Intercept Pharma (ICPT) Said to Explore Sale Following Interest
Get Alerts ICPT Hot Sheet
Join SI Premium – FREE
(Updated - February 12, 2016 12:29 PM EST)
Intercept Pharma (NASDAQ: ICPT) said to explore sale after interest, according to Reuters.
UPDATE - Earlier in February, the U.K.'s Daily Mail said Intercept might put itself up for sale. The list of potential suitors was said to include Shire plc (Nasdaq: SHPG), Gilead Sciences (Nasdaq: GILD), Bristol-Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE).
Shares of Intercept are positive Friday, but the stock is still down over 50 percent versus the same period last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shift4 CEO says bids from suitors did not adequately value the firm; shares down
- HashiCorp, Inc (HCP) Is Said To Weigh Potential Sale - Bloomberg
- Qatar Airways mulls up to 150 widebody orders from Boeing and Airbus - Bloomberg
Create E-mail Alert Related Categories
Mergers and Acquisitions, Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!